Embed Size (px)
Citation preview
Confidential 1
PharmAbcine, Inc.
Jin-San Yoo [email protected]
BioDeutschland 2013, September 23, Duesseldorf
Confidential
AGENDA
1.PharmAbcine Intro and Its pipelines
2.What we are looking for
3.Conclusion
Confidential
PharmAbcine?
Clinical stage biotech company focus on fully human therapeutic
Antibody and Next Generation of Bispecific Antibodies Therapeutics
for Cancer Patients.
High quality fully human antibody phage display library
Next-generation dual targeted bispecific antibody platform and its
innovative pipelines.
270 Patients derived cancer stem cells (CSCs) libraries and its animal
model system.
Established on Sep. 3rd, 2008 and succeeded to closed series A funding in
the middle of global economy crisis co-leaded by Novartis Venture Fund
and OrbiMed.
Tanibirumab, the leading pipeline is heading to the end of Phase I.
Confidential
PharmAbcine (cont.)
Address Daejeon, South Korea
Web site http://www.pharmabcine.com
Established year Sep. 2008
Number of Employees 29 (Ph.D 6, MS 13)
Capital 342, 437, 000 KRW ( 684,874 shares)
Pipelines Tanibirumab, PMC-001, PMC-201, etc
Technologies & Holdings DIG-body, PIG-body, Patients Derived Cancer Stem Cell Library,
Phage Display Human Antibody Libraries
Investors
OrbiMed, Novartis Venture Fund, Oxford Bioscience Partners,
Green Cross Pharma, Dong Yang Investment, KBI, MIRAE Asset
etc.
BOD Chairman: Dr. Jin San Yoo (PharmAbcine)
Directors: Dr. Guan Lee Ang (Novartis)
Dr. Hongbo Lu (OrbiMed)
Dr. Sang Hoon Lee (PharmAbcine)
Dr. Min Cheol Shin (Dong Yang Investment)
Dr. Christopher B. Kim (Oxford Bioscience Partners)
Mr. Young Kwon Ku (MVP capitals)
SAB Chairman: Dr. Waun Ki Hong (M.D. Anderson Cancer Institute)
Dr. Dong Moon Shin (Winship Cancer Institute)
Dr. Do Hyun Nam (Samsung Cancer Center
Confidential
Management
Confidential
Dr. Sang Hoon Lee
Vice President & CSO
Dr. Jin-San Yoo
President & CEO
08 -
present
PharmAbcine (CEO &
President)
06 - 09 KRIBB (Chief Scientist)
01 - 06 LG Life Sciences, ltd (Chief
Scientist)
98 - 01 The Scripps Research Institute
(TSRI senior scientist)
96 - 98 HHMI at Stanford Univ. School
of Medicine (HHMI Fellow)
88 - 96 Max-Planck Institute for BPC
(Intern, MS, Ph.D, MPI Fellow)
84 - 90 Georg-August University
Göttingen (Vor-Diplom, Diplom)
09-
present
PharmAbcine (VP)
08- 09 Exelixis (Senior Scientist II )
05 - 08 Genentech (Group Leader/Scientist)
05 - 05 AstraZeneca (Principal Scientist)
01 - 05 Chiron (Principal Scientist)
98 - 00 Stanford Univ. School of Medicine
(Research Associate)
97 - 98 UCSF & Glad Stone Institute
(Post Doc.)
94 - 97 Harvard Medical School (Post Doc.)
89 - 94 Ohio State Univ. (Ph.D.)
82 - 86 Seoul National Univ. (BS and MS)
Confidential
Scientific Advisory Boards
Waun Ki Hong
MD/Ph.D,
(MD Anderson Cancer Center)
Do Hyun Nam
MD/Ph.D
(Samsung Medical Center)
• PharmAbcine SAB (Chairman)
• M.D. Anderson Cancer Center
(Division Head)
• Texas School of Medicine (Professor)
• America Cancer Advisory Board
• 2001-2002 AACR(President)
• AACR honored Joseph H. Burchenal
and the Rosenthal Foundation Awards
• David A. Karnofsky Awards
• Director at Institute for Refractory
Cancer Research at Samsung
Medical Center
• Sung Kyun Kwan Univ. School of
Medicine (Professor)
• Cancer Stem Cell Research Center
at Samsung Medical Center(Director)
• Samsung Medical Center QA Clinic
Center
• Seoul National Univ. School of
Medicine (MD/Ph.D)
• Emory Winship Cancer Institute as
Professor of Hematology and
Oncology, and Otolaryngology;
• Associate Director of Academic
Development for Emory Winship
Cancer Institute
• Director of the Emory Winship
Cancer Chemoprevention
Program.
Dong Moon Shin
MD/FACP,
(Winship Cancer Center)
Confidential
Innovative Pipeline Focused on Oncology
Early Stage
Research
(In Vitro
Lead)
Late Stage
Research
(Preclinical
Stage)
Phase III Phase I Phase II
Today
Today
Today
Tanibirumab
(TTAC-0001;
Anti-KDR mAb)
PMC-001, Bi-specific
Antibody Targeting
KDR & Tie-2
PMC-xxx, Bi-specific
Antibodies Targeting
Cancer Pathways
Today
PMC-201, Bi-specific
Antibodies Targeting
Cancer Stem Cells
Fast-track Approval in GBM
2015
Additional Solid Tumor Trials
IND 2017
IND
Early 2015
Clinical PoC &
Partnership 2016
IND 2016
Confidential
Leading Pipeline: Tanibirumab
Tanibirumab, anti-hVEGFR-2(=KDR) neutralizing fully human IgG1 isolated from
PharmAbcine library. It shows significant anti-angiogenic as well as anti-tumoric
activity in both murine and human cancer animal model systems. Due to its
unique cross-species cross reactivity in murine counterpart, its in vivo and
translational research are available, which is the unique feature among other
anti-VEGFR-2 mAbs. Its epitope is novel, conformational dependent and
discontinued manner.
(http://clinicaltrials.gov/ct2/show/NCT01660360?term=tanibirumab&rank=1).
IP status of Tanibirumab
Title: Human Monoclonal Antibody Neutralizing Vascular Endothelial Growth
Factor Receptor and Use Thereof
Registered Countries Korea, Japan, China, Singapore
Application Pending
Countries
US, Canada, Australia, EP
Confidential
Tanibirumab (Cont.)
Efficacy of TTAC-0001 vs. Avastin in U87-MG
GBM Orthotopic Model
Tanibirumab also shows strengthened efficacies in
A549 Lung Cancer model
– Efficacy: Tanibirumab = Avastin
– Apoptosis: Tanibirumab = Avastin
Efficacy of MCF-7 Breast Cancer model
– Tanibirumab > Avastin
Inhibition of Metastasis in MCF-7 model
Tanibirumab > Avastin
Additive/Synergic effect in combination of - CPT-11 +
Tanibirumab in Colo205 model
- Combination of 5-FU + TTAC-0001 in
- Colo205 model
Efficacy in Hep3B liver model
Preclinical Data
Clinical Data
- Up to cohorts 8 (24 mg/kg) has no DLT observed!
- Preliminary data (PK/PD) from Phase I suggest that increase of some plasma
biomarkers (VEGF-A, sVEGFR-2, PIGF) were observed.
- No common side effects like hypertension and hemorrhage appeared in
Ramucirumab, Avastin, Sutent, Nexava and other VEGF antagonists.
- Several SD patients from all terminal staged cancer patients in PI.
Confidential
WHY KDR?
• Angiogenesis is correlated with
disease progression in many
tumor types.
• Angiogenesis has been
correlated with poor prognosis
in colon, lung, breast
&
renal
cancers.
• VEGF and KDR(VEGFR2) are
overexpressed in most malignant
tumors, tumor endothelium, CEC
EPC, Cancer Stromal, and CSC.
• Both Paracrine and autocrine
VEGF and KDR signaling
are key regulator for tumor
angiogenesis and cancer
pathogenesis.
Confidential
Bispecific Platforms: DIG-Body & PIG-Body
Dual specific antibody platform, both DIG-body and PIG-body, are being developed
for the next generation therapeutics. Those technologies adopted a full IgG format
for single therapy, and showed superior efficacy to mono specifics.
IgG + Domain = DIG-Body IgG + Peptide = PIG-Body
Confidential
DIG-Body Pipeline: PMC-001 (=DIG-KT)
Avastin resistance tumor bypass VEGF-KDR and utilize PDGF-PDGFR, FGF-
FGFR, HGF-cMET, VEGF-C, VEGF-D, VEGF-R3, and ANG-TIE2.
KDR and TIE2 are co-localized in the cavolae of single cell and have potential
biologically functional complementary relationship.
Neutralizing both VEGF-KDR and ANG-Tie2 Pathways results in superior efficacy
and manage Avastin resistant GBM growth.
Potential effector functions are preserved.
IP status of PMC-001(=DOG-KT)
Title: Dual Targeting Antibody of Novel Form, And Use Thereof
Registered Countries Korea
Application Pending
Countries
US, Canada, Australia, EP, Singapore, Japan, China, Brazil, Russia,
India
Confidential
PMC-001 (=DIG-KT)
PMC-001 is superior to Tanibirumab in Hep3B
liver cancer model
Preclinical Data
PMC-001 overcomes Avastin-resistant GBM
orthotopic cancer model
PMC-001 inhibited the growth of
pancreatic tumors and metastasis
Confidential
What we are looking for:
• Out-licensing Opportunity for Tanibirumab.
• Out-Licensing Opportunity for DIG-KT.
• Co-development opportunity for early stage novel DIG-
Bodies and PIG-Bodies.
• 10 MM USD funding from single Strategic Investor for
PharmAbcine IPO in 2014.
• Research collaborators like SANOFI, LG Life Science
and GreenCross Pharma.
• Customer for our fee based service.
Confidential
Conclusions:
• Tanibirumab is superior to Avastin and more valuable than Ramucirumab.
• Tanibirumab Phase I has no DLT and no side effects like hypertension and
hemorrhage which are very common in all angiogenesis inhibitors. It will
be completed in 2013.
• Both DIG-body and PIG-body platform are novel and can generate new
pipelines.
• DIG-KT shows excellent efficacy in various tumor models and is being
studied in pre-clinical stage and scheduled to be IND-filed at late 2014.
• Several novel DIG-bodies and PIG-Bodies molecules are in study and
looking for partnership.
• PharmAbcine will go to IPO for the KOSDAQ market in 2014. And the
company is looking for a strategic investor with 10 MM USD, co-
development partners and out licensing opportunity for Tanibirumab and
DIG-KT.
Confidential
Clinical Value to Patients
DIG-Body
PIG-Body Tanibirumab Avastin <<< <<
First in class!
Best in class!
2004
Making Ramucirumab
into history!
2016?
Making Cancer
into history!
2018?
<< Ramu-
cirumab
Making Avastin
into history!
2015?
Confidential
Contact
Jin-San Yoo,
Dr. rer. nat. Diplom Biol.
President & CEO
PharmAbcine, Inc
461-8, Daejeon BioVentureTown, Jeonmin-Dong,
Yusong-Gu, Daejon, 305-811
Republic of Korea
T: +82-42-863-2019 M: +82-10-7430-1660,
F: +82-42-863-2080
Email: [email protected],
http://www.PharmAbcine.com
Confidential
Thank you very much for your attention!
